| Date Filed | Type | Description |
| 08/14/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 07/31/2023 |
8-K
| Quarterly results |
| 07/24/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
3
| HOGAN H MICHAEL III (CEO) has filed a Form 3 on Nabriva Therapeutics plc |
| 07/10/2023 |
3
| Maggio David (CFO) has filed a Form 3 on Nabriva Therapeutics plc |
| 07/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/01/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/15/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 04/17/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/31/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 01/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/20/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/10/2023 |
4
| Gelone Steven P. (President and COO) has filed a Form 4 on Nabriva Therapeutics plc|
Txns:
| Paid exercise price by delivering 5 shares
@ $1.3, valued at
$6.5 |
|
| 01/10/2023 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc|
Txns:
| Paid exercise price by delivering 11 shares
@ $1.3, valued at
$14.3 |
|
| 01/09/2023 |
8-K
| Termination of a Material Definitive Agreement, Cost Associated with Exit or Disposal Activities, Other Events, Financial Sta... |
| 01/04/2023 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc|
Txns:
| Paid exercise price by delivering 5 shares
@ $1.89, valued at
$9.5 |
|
| 01/04/2023 |
4
| Gelone Steven P. (President and COO) has filed a Form 4 on Nabriva Therapeutics plc|
Txns:
| Paid exercise price by delivering 3 shares
@ $1.89, valued at
$5.7 |
|
| 12/08/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/08/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/28/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/08/2022 |
4
| Gelone Steven P. (President and COO) has filed a Form 4 on Nabriva Therapeutics plc|
Txns:
| Paid exercise price by delivering 4 shares
@ $2.2392, valued at
$9 |
|
| 11/08/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc|
Txns:
| Paid exercise price by delivering 10 shares
@ $2.2392, valued at
$22.4 |
|
| 11/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/01/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/11/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc|
Txns:
| Paid exercise price by delivering 9 shares
@ $2.72, valued at
$24.5 |
|
| 10/11/2022 |
4
| Gelone Steven P. (President and COO) has filed a Form 4 on Nabriva Therapeutics plc|
Txns:
| Paid exercise price by delivering 4 shares
@ $2.72, valued at
$10.9 |
|
| 10/04/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/04/2022 |
4
| Schroeder Theodore R (CEO) has filed a Form 4 on Nabriva Therapeutics plc|
Txns:
| Paid exercise price by delivering 5 shares
@ $2.08, valued at
$10.4 |
|
| 10/04/2022 |
8-K
| Other Events Interactive Data |
|